Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen-Reference-Cited by-同舟云学术

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen

Published:2001 Issue:3 Volume:65 Page:445-448
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J. Med. Virol.

Author:

Delaugerre C.,Rohban R.,Simon A.,Mouroux M.,Tricot C.,Agher R.,Huraux J.M.,Katlama C.,Calvez V.

Publisher

Wiley

Subject

Infectious Diseases,Virology

Reference17 articles.

1. Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy

2. 1999. Efavirenz responses in NNRTI experienced patients : results from the SUSTIVA® expanded access program. 39th ICAAC. September 26-29. San Franscisco, California.

3. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen

4. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective study of the prevalence of acquired drug resistance after failed antiretroviral therapy in Libya;E MEDITERR HEALTH J;2024

2. Pretreatment and Acquired Drug Resistance in Children With Human Immunodeficiency Virus Type 1 in Jos, Nigeria;Open Forum Infectious Diseases;2024-02-19

3. Novel 2-D phosphorene-based drug delivery system for anti-HIV zidovudine drug to enhance the therapeutic effects: A first-principles based study;Computational and Theoretical Chemistry;2023-11

4. Future perspectives of antiviral therapy;Viral Infections and Antiviral Therapies;2023

5. Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance;Antimicrobial Agents and Chemotherapy;2022-05-17